Open Access
Table 2.
Results of pharmacoeconomical analysis “7+3” in chemotherapy of patients with acute myeloid leukemia (“Cost-Effectiveness” Method”)
| Data on the effectiveness of different chemotherapy schemes and cost indicators associated with their use in hospital settings | ||||
|---|---|---|---|---|
| Achieving complete remission, (% of patients) 13 | Total medical expenses | CEA indicator | ||
| UAH. | US $ | UAH/ per unit efficiency | US $/ per unit efficiency | |
| Group of patients #1: (scheme N1): daunorubicin 60 mg mg/m2 per day on the 1st‐3rd day; citarabin – 100 mg/m2/day on the 1st‐7th day. | ||||
| 41,2 | 19689,45 | 831,48 | 477,86 | 20,18 |
| Group of patients #2 (scheme N2): daunorubicin 60 mg mg/m2 per day on the 1st‐3rd day; citarabin‐200 mg/m2/day on 1st‐7th day. | ||||
| 66,5 | 30269,67 | 1278,28 | 455,13 | 19,22 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.